Tegafur
Highest phase reached
Approved
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Tegafur
- Molecular weight
- 200.17
- Structure (SMILES)
- O=c1[nH]c(=O)n(C2CCCO2)cc1F
- citofur
- Citofur
- riol
- Riol
- tegafur component of s 1
- Tegafur component of s-1
- tegafur component of teysuno
- Tegafur component of teysuno
- tegafur component of ts 1
- Tegafur component of ts-1
- uftoral
- Uftoral
- atillon
- Atillon
- bms 200604
- BMS-200604
- camrelizumab oxaliplatin tegafur
- coparogin
- Coparogin
- exonal
- Exonal
- fental
- Fental
- franrose
- Franrose
- ft 207
- FT-207
- ftorafur
- Ftorafur
- fulaid
- Fulaid
- fulfeel
- Fulfeel
- furafluor
- Furafluor
- furofutran
- Furofutran
And 50 more, listed on the interactive page.
- CAS registry numbers
- 17902-23-7
- ChEMBL ID
- CHEMBL20883
- InChIKey
- WFWLQNSHRPWKFK-UHFFFAOYSA-N
- PubChem compound IDs
- 5386
- RxNorm IDs (RxCUI)
- 4582
- FDA ingredient codes (UNII)
- 1548R74NSZ
- L01BC03
- L01BC53
Sources for recorded values
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- tegafur
- Type
- Synthetic organic
- Approval recorded by Guide to Pharmacology
- Yes
- Mechanism
- DNA inhibitor
- Action type
- Inhibitor
- Target
- DNA
- Mechanism
- RNA inhibitor
- Action type
- Inhibitor
- Target
- RNA
- Mechanism
- Thymidylate synthase inhibitor
- Action type
- Inhibitor
- Target
- Thymidylate synthase
- Protein identifier
- P04818
Open Targets mechanisms
- Mechanism
- Thymidylate synthase inhibitor
- Action type
- Inhibitor
- Target
- Thymidylate synthase
- Condition
- Stomach Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000178
- Subject identifier
- D013274
- Condition
- Carcinoma, Squamous Cell
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000181
- Subject identifier
- D002294
- Condition
- Carcinoma, Hepatocellular
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000182
- Subject identifier
- D006528
- Condition
- Squamous Cell Carcinoma of Head and Neck
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000199
- Subject identifier
- D000077195
- Condition
- Adenocarcinoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000228
- Subject identifier
- D000230
- Condition
- Colorectal Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000365
- Subject identifier
- D015179
- Condition
- Stomach Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000503
- Subject identifier
- D013274
- Condition
- Neoplasms
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Small Cell Lung Carcinoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000702
- Subject identifier
- D055752
- Condition
- Liver Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001421
- Subject identifier
- D008107
- Condition
- Pancreatic Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0002618
- Subject identifier
- D010190
- Condition
- Esophageal Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0002916
- Subject identifier
- D004938
- Condition
- Carcinoma, Non-Small-Cell Lung
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003060
- Subject identifier
- D002289
- Condition
- Kidney Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003086
- Subject identifier
- D007674
- Condition
- Pancreatic Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003860
- Subject identifier
- D010190
- Condition
- Breast Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003869
- Subject identifier
- D001943
- Condition
- Biliary Tract Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003891
- Subject identifier
- D001661
- Condition
- Stomach Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003897
- Subject identifier
- D013274
- Condition
- Colorectal Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004142
- Subject identifier
- D015179
- Condition
- Cholangiocarcinoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0005221
- Subject identifier
- D018281
- Condition
- Esophageal Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0005922
- Subject identifier
- D004938
- Condition
- Head and Neck Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0006859
- Subject identifier
- D006258
- Condition
- Neuroendocrine Tumors
- Highest recorded phase
- 2
- Condition identifier
- EFO:1000045
- Subject identifier
- D018358
- Condition
- Pancreatic Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:1000359
- Subject identifier
- D010190
- Condition
- Rectal Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:1000657
- Subject identifier
- D012004
And 18 more, listed on the interactive page.
- Condition identifier
- EFO_0000181
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000182
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000199
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000365
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000503
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000616
- Condition identifier
- EFO_0000702
- Highest recorded phase
- 2
- Condition identifier
- EFO_0002618
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003060
- Condition identifier
- EFO_0003086
- Highest recorded phase
- 1
- Condition identifier
- EFO_0003860
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003897
- Condition identifier
- EFO_0004142
- Highest recorded phase
- 2
- Condition identifier
- EFO_0005221
- Highest recorded phase
- 3
- Condition identifier
- EFO_0005922
- Highest recorded phase
- 3
- Condition identifier
- EFO_0006859
- Condition identifier
- EFO_1000359
- Highest recorded phase
- 2
- Condition identifier
- EFO_1000657
- Highest recorded phase
- 3
- Condition identifier
- EFO_1001956
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0001056
- Condition identifier
- MONDO_0001056
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0001187
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0002120
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002169
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0002974
And 42 more, listed on the interactive page.
- Event
- acute myeloid leukaemia
- Reports
- 4
- Reporting signal score
- 8.74867
- Event
- alanine aminotransferase increased
- Reports
- 29
- Reporting signal score
- 62.5694
- Event
- anaemia
- Reports
- 18
- Reporting signal score
- 15.454
- Event
- anorexia
- Reports
- 8
- Reporting signal score
- 21.137
- Event
- aspartate aminotransferase increased
- Reports
- 26
- Reporting signal score
- 56.1503
- Event
- bile culture positive
- Reports
- 1
- Reporting signal score
- 7.58686
- Event
- biliary tract disorder
- Reports
- 2
- Reporting signal score
- 7.0277
- Event
- blood bilirubin increased
- Reports
- 13
- Reporting signal score
- 29.2243
- Event
- blood lactate dehydrogenase increased
- Reports
- 8
- Reporting signal score
- 18.309
- Event
- bone marrow failure
- Reports
- 18
- Reporting signal score
- 48.3854
- Event
- carbohydrate antigen 15-3 increased
- Reports
- 2
- Reporting signal score
- 8.58673
- Event
- cardiotoxicity
- Reports
- 5
- Reporting signal score
- 12.6017
- Event
- cholangitis acute
- Reports
- 2
- Reporting signal score
- 7.8713
- Event
- decreased appetite
- Reports
- 21
- Reporting signal score
- 27.4507
- Event
- diarrhoea
- Reports
- 41
- Reporting signal score
- 35.4556
- Event
- disease progression
- Reports
- 9
- Reporting signal score
- 8.5991
- Event
- disseminated intravascular coagulation
- Reports
- 6
- Reporting signal score
- 15.0951
- Event
- eosinophil count increased
- Reports
- 3
- Reporting signal score
- 6.25957
- Event
- eosinophil percentage increased
- Reports
- 2
- Reporting signal score
- 7.80229
- Event
- febrile neutropenia
- Reports
- 7
- Reporting signal score
- 6.55445
- Event
- gamma-glutamyltransferase increased
- Reports
- 6
- Reporting signal score
- 9.11971
- Event
- hepatic function abnormal
- Reports
- 19
- Reporting signal score
- 45.7949
- Event
- hyperbilirubinaemia
- Reports
- 6
- Reporting signal score
- 14.4356
- Event
- hypoalbuminaemia
- Reports
- 3
- Reporting signal score
- 6.28463
- Event
- interstitial lung disease
- Reports
- 8
- Reporting signal score
- 10.7618
And 28 more, listed on the interactive page.
- NCT00002801
- NCT00004860
- NCT00152230
- NCT00209651
- NCT00284258
- NCT00378716
- NCT00385970
- NCT00660894
- NCT00905047
- NCT00974389
- NCT03397199
- NCT03769935
- NCT00003925
- NCT00009815
- NCT00009828
- NCT00400023
- NCT00479076
- NCT01128998
- NCT01610479
- NCT02454062
- NCT04566380
- NCT00005608
- NCT00152178
- NCT00152191
- NCT00994968
And 240 more, listed on the interactive page.
- Hydrogen bond acceptors
- 4
- Hydrogen bond donors
- 1
- Polar surface area
- 64.09
- Calculated partition coefficient (ALogP)
- -0.02
- Calculated partition coefficient (XLogP)
- -0.3
- Prodrug
- Yes
- Chirality
- Racemic
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 1
- Heavy atoms
- 14
- Molecular formula
- C8H9FN2O3
- Monoisotopic mass
- 200.05972032
- Natural product
- No
- Recorded assays
- 2,225
- Active assays
- 19
- Confirmatory
- Other
- Screening
- Antimetabolites, Antineoplastic
Related records
Trials (67)
- A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study
- A Phase II Study of Gimatecan (ST1481) in Locally Advanced or Metastatic Pancreatic Cancer
- A Phase II Study of Paclitaxel, UFT, and Leucovorin in Patients With Metastatic Esophageal Cancer
- A Phase II Study of Tegafur-Uracil as Maintenance Chemotherapy in Patients With Stage II of Colon Cancer
- A Phase II Study of Tegafur/Uracil (UFUR®)Plus Thalidomide for the Treatment of Advanced or Metastatic Hepatocellular Carcinoma (HCC)
- A Phase III Trial Comparing UFT+PSK to UFT+LV in Stage IIB, III Colorectal Cancer
- A Phase lb/lI Clinical Study in Advanced or Metastatic Esophageal Squamous Cell Carcinoma
- A Randomized Controlled Study of Postoperative Adjuvant Chemotherapy of Uracil- Tegafur (UFT) Compared With Surgery Alone (NSAS-CC)
- A Randomized Controlled Study of Postoperative Adjuvant Chemotherapy of Uracil- Tegafur (UFT) Compared With Surgery Alone (NSAS-GC)
- A Randomized Controlled Study of Postoperative Adjuvant Therapy of Uracil-tegafur (UFT) Compared With Cyclophosphamide/Methotrexate/5-fluorouracil (CMF) in Breast Cancer (NSAS-BC)
- A Study of Intraperitoneal Paclitaxel in Combination With SOX Compared With SOX Alone in Gastric Cancer With Malignant Ascites
- A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Extrapancreatic Neuroendocrine Tumor
- A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine Tumor
- Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the HER-2 Positive GC/GEJC
- Adoptive Transfer of iNKT Cells for Treating Patients With Relapsed/Advanced HCC
- Adoptive Transfer of Specific HCC Antigens CD8+ T Cells for Treating Patients With Relapsed/Advanced HCC
- Apapitatin Combined With SOX for Palliative Adjuvant Chemotherapy in Patients With Advanced Gallbladder Carcinoma
- Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric Cancer
- Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer
- CCRT Followed by Tegafur, Gimeracil and Oteracil Potassium in Cervical Cancer
Approved for (2)
- Cancer
- Neoplasm
In development for (40)
- Adenocarcinoma Phase 3
- Adult hepatocellular carcinoma Phase 2
- Biliary tract cancer Phase 3
- Biliary tract neoplasm Phase 3
- Breast cancer Phase 3
- Breast neoplasm Phase 3
- Carcinoma of esophagus Phase 3
- Cervical cancer Phase 1
- Cholangiocarcinoma Phase 3
- Colorectal adenocarcinoma Phase 3
- Colorectal cancer Phase 3
- Colorectal neoplasm Phase 3
- Esophageal cancer Phase 3
- Esophageal squamous cell carcinoma Phase 3
- Exocrine pancreatic carcinoma Phase 3
- Gallbladder carcinoma Phase 2
- Gastric adenocarcinoma Phase 3
- Gastric cancer Phase 3
- Gastric carcinoma Phase 3
- Gastric neoplasm Phase 3
Targets (1)
- TYMS Thymidylate synthase inhibitor